Analyst consensus rating
Summit Therapeutics Analyst Rating: Buy
Direct answer
Summit Therapeutics's consensus rating is Buy.
13 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $28.44.
Forecast evidence checked September 8, 2026.
Get free Summit Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $17.28
- Average price target
- $28.44
- High price target
- $41.72
- Low price target
- $11.00
- Low target gap
- -36.3%
- Target upside
- +64.6%
- High target gap
- +141.5%
- Target range width
- 177.8%
- Consensus rating
- Buy
- Analysts
- 13
- Evidence date
- September 8, 2026
- Valid through
- September 15, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Summit Therapeutics?
Summit Therapeutics has a verified Buy consensus. The same dataset has an average price target of $28.44.
How far are Summit Therapeutics's low and high targets from the recorded price?
The low target implies -36.3%, while the high target implies +141.5%.
How many analysts are included in Summit Therapeutics's consensus?
The verified consensus includes 13 analysts.
How is Summit Therapeutics's target upside or downside calculated?
The average target of $28.44 is divided by the recorded price of $17.28, then one is subtracted to produce +64.6%. This does not guarantee a future return.
When was Summit Therapeutics's analyst forecast verified?
The data was verified on 2026-09-08. The dataset is valid through 2026-09-15.